Huaren Pharmaceutical Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Liang Hong

Algemeen directeur

CN¥970.6k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	1.9yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.5yrs
Gemiddelde ambtstermijn bestuur	2.6yrs

Recente managementupdates

Recent updates

CEO

Liang Hong (53 yo)

1.9yrs

Tenure

CN¥970,600

Compensatie

Mr. Liang Hong is Executive CEO of Huaren Pharmaceutical Co. Ltd. from December 29, 2022.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Liang Hong	Executive CEO	1.9yrs	CN¥970.60k	geen gegevens
Jian Lin	President	1.2yrs	CN¥588.50k	geen gegevens
Liping Han	VP & CFO	4.1yrs	CN¥880.90k	geen gegevens
Xiangyuan Meng	VP & Board Secretary	less than a year	geen gegevens	geen gegevens

1.5yrs

Gemiddelde duur

40.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 300110 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Genfu Feng	Independent Director	5.3yrs	CN¥100.00k	geen gegevens
Tianxi Zhang	Independent Director	5.3yrs	CN¥100.00k	geen gegevens
Xiaodong Yang	Chairman	5.3yrs	CN¥3.05m	0.11% CN¥ 5.0m
Li Qiang	Chairman of the Supervisory Board	5.3yrs	geen gegevens	geen gegevens
Xuefei Jia	Supervisor	2.6yrs	geen gegevens	geen gegevens
Subin Zhu	Non-Independent Director	2.6yrs	geen gegevens	geen gegevens
Chuanwen Dong	Non-Independent Director	2.6yrs	geen gegevens	geen gegevens
Yong Liu	Independent Director	2.8yrs	CN¥100.00k	geen gegevens
Zhihua Huang	Non-Independent Director	1.2yrs	geen gegevens	geen gegevens
Yan Dong	Non-Independent Director	1.2yrs	geen gegevens	geen gegevens
Junwei Song	Employee Representative Supervisor	1.8yrs	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300110 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.6 jaar), wat duidt op een nieuw bestuur.

Huaren Pharmaceutical Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Huaren Pharmaceutical Co., Ltd., Annual General Meeting, May 16, 2024

High number of new directors

Huaren Pharmaceutical Co., Ltd. Announces Director Appointments

Huaren Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2023

High number of new and inexperienced directors

Huaren Pharmaceutical Co., Ltd. Approves Board Appointments

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.019 (vs CN¥0.046 in 3Q 2023)

Investor sentiment deteriorates as stock falls 15%

New minor risk - Dividend sustainability

Investor sentiment improves as stock rises 29%

Huaren Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

New minor risk - Financial position

Dividend of CN¥0.021 announced

Huaren Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

New minor risk - Dividend sustainability

Huaren Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.035 in 1Q 2023)

Huaren Pharmaceutical Co., Ltd., Annual General Meeting, May 16, 2024

Now 20% undervalued after recent price drop

Huaren Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Now 23% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 16%

New minor risk - Profit margin trend

Huaren Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024

High number of new directors

Huaren Pharmaceutical Co., Ltd. Announces Director Appointments

New minor risk - Profit margin trend

Huaren Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022

Huaren Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2023

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.11 in FY 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.041 (vs CN¥0.041 in 2Q 2021)

Investor sentiment improved over the past week

Huaren Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on June 17, 2022

High number of new and inexperienced directors

Huaren Pharmaceutical Co., Ltd. Approves Board Appointments

Huaren Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2021

Huaren Pharmaceutical Co., Ltd., Annual General Meeting, Apr 21, 2022

Full year 2021 earnings released: EPS: CN¥0.11 (vs CN¥0.08 in FY 2020)

Huaren Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021

Third quarter 2021 earnings released: EPS CN¥0.037 (vs CN¥0.016 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.041 (vs CN¥0.025 in 2Q 2020)

Huaren Pharmaceutical Co., Ltd. Proposes Cash Dividend on A Shares for the Year 2020, Payable on June 4, 2021

First quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.005 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.08 (vs CN¥0.036 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.08 (vs CN¥0.036 in FY 2019)

Huaren Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 20, 2021

New 90-day low: CN¥4.28

New 90-day low: CN¥4.55

New 90-day low: CN¥4.89

Huaren Pharmaceutical Co., Ltd. (SZSE:300110) agreed to acquire Guangxi Yuyuan Pharmaceutical Co., Ltd. and Pubei Xinke Pharmaceutical Packaging Co., Ltd. from Ruan Chuanming, Ruan Yingle and He Hui for approximately CNY 390 million.

Third quarter earnings released

Huaren Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

New 90-day high - CN¥4.89

First half earnings released

New 90-day high - CN¥4.79

Huaren Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 14, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd